How Moderna’s mRNA Platform Builds Bespoke Cancer Vaccines
A new personalized mRNA vaccine for melanoma cut the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial. Behind this headline result lies a complex scientific mechanism that allows laboratories to manufacture an individualized medicine tailored to a single patient in just over nine weeks.
Moderna focuses on RNA therapeutics, primarily mRNA vaccines, which use messenger RNA to carry instructions for proteins to produce an immune response according to background information from the company. The company has 44 treatment and vaccine candidates, including three cancer vaccines, with 37 having entered clinical trials. Founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan, the company raised US$2 billion in venture capital funding between 2011 and 2017. Stéphane Bancel was appointed as chief executive officer in 2011. In May 2026, Time ranked Moderna first in their list of the World’s Most Impactful Companies.
The personalized melanoma vaccine, called intismeran autogene, uses genomic data from a patient’s tumor according to details provided by NBC News. The creation process begins by sequencing the excised tumor’s genome to identify abnormal proteins known as neoantigens. Each personalized vaccine then trains the immune system to recognize and target these specific neoantigens, functioning in a manner similar to how standard vaccines target viruses and bacteria. Dr. Georgina Long, co-medical director of the Melanoma Institute Australia who led the clinical trial, explained that the treatment is designed to clear away invisible cancer cells that might still be lurking after surgery. Keytruda works by mobilizing T cells to spot and destroy cancer, and the vaccine pairs with this immunotherapy to help the immune system fight the disease.
The manufacturing speed relies on messenger RNA technology, the same platform pioneered in the development of Covid-19 vaccines. According to trial data reported by NBC News, patients received their personalized vaccine in a little over nine weeks on average. Dr. Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Center and president-elect of the American Association for Cancer Research, noted that these treatments are not kept on a shelf and must be made for each individual patient.
The late-stage trial evaluated 1,137 Stage 3 melanoma patients who had undergone surgery to remove their tumors and were treated with Merck’s immunotherapy drug Keytruda, as reported by NBC News. Out of the total participants, 757 received the personalized vaccine alongside Keytruda, while 380 received a placebo alongside Keytruda. The results showed that two years later, 82% of patients who received the vaccine and immunotherapy had no recurrence, compared with 70% in the placebo group. This combination therapy cut the risk of melanoma recurrence or death by 42% compared with standard treatment. Vonderheide described the results as a game changer and the first step toward using cancer vaccines to their full potential.
For patients facing a diagnosis where cancer has spread to nearby lymph nodes or other sites on the skin, recurrence is a dreaded event because it raises the risk of spreading to distant organs. The therapy carries significant weight for Moderna’s growth story because its other approved commercial products are respiratory vaccines, including Spikevax and Mnexspike for COVID-19, Mresvia for respiratory syncytial virus, and Mflusiva for influenza. Following the data release, Moderna’s stock fell 4% to $193.62, extending an 18% plunge from the prior session according to 24/7 Wall St., as the market reacted to full trial data that landed short of the loftiest hopes built during a months-long rally. Medical results and treatment suitability vary by individual, so patients should always consult their doctor or oncologist regarding personal medical decisions.
Partnerships and Early Ventures in Oncology
Moderna’s entry into cancer therapeutics began with the creation of Onkaido Therapeutics in January 2014. This first venture was established to focus exclusively on developing mRNA-based oncology treatments. The company later formed a partnership with Merck in 2015 to develop treatments for cancer, a collaboration that continues to underpin the current melanoma vaccine program. In January 2015, Moderna launched its second venture, Valera, which focused on viral, bacterial, and parasitic infectious diseases. Employees of Valera and Moderna subsequently developed an mRNA vaccine candidate against Zika virus infection.
Another venture, Elpidera, was announced in May 2015 to continue work on RNA therapies and advance Moderna’s work with Alexion. In 2014, the company entered an agreement with Alexion Pharmaceuticals to develop treatments against ten diseases. However, in 2017, Alexion terminated its partnership with Moderna after safety issues prevented their work from reaching human trials. These early strategic moves illustrate the company’s broader approach to diversifying its RNA platform beyond respiratory vaccines into complex oncological and infectious disease applications.
Market Reaction and Competitive Context
Despite the positive clinical outcomes, Moderna’s stock fell 4% to $193.62, extending an 18% plunge from the prior session according to 24/7 Wall St. The market reaction reflected a revaluation of the vaccine’s worth, as the data landed short of the loftiest hopes built during a months-long rally that began in August when the trial met its primary goal. In contrast, Merck stock, which co-developed the vaccine, was down only 0.8% to $146, while Pfizer slipped 0.7% to $30.22. The iShares Biotechnology ETF remained unchanged at $209.54, indicating the decline was specific to Moderna.
The disparity in stock performance stems from the vaccine’s central role in Moderna’s growth story, as all of the company’s approved commercial products are respiratory vaccines. For Merck, the vaccine serves as an add-on to Keytruda, its blockbuster cancer drug, which already supports its oncology business. Analysts noted that the results, while near expectations, showed a smaller benefit than an earlier, smaller trial produced in a different patient group. This concentration of value in oncology left Moderna stock more exposed to the gap between the data and prior investor hype.
Sources
- Moderna
- Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
- Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Photo: Xuthoria (CC BY-SA 4.0)
